The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
This a continuation of 08/191,973 which was filed Feb. 04, 1994, now U.S. Pat. No. 5,772,992, which is a continuation-in-part of international application PCT/US93/11198 which was filed on Nov. 22, 1993 and which entered the U.S. national stage under 35 U.S.C. .sctn.371 on Apr. 06, 1995 as Ser. No. 08/411,296, now U.S. Pat. No. 5,677,149; which is continuation-in-part of U.S. Ser. No. 07/981,044; was filed Nov. 24, 1992 which is now abandoned.
A method of treating cardiac or myocardial conditions comprises the administration of an effective amount of autologous bone marrow. The bone marrow may optionally be stimulated and/or administered in combination with a pharmaceutical drug, protein, gene or other factor or therapy that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation or migration or blood vessel formation.
The present invention relates to granulocyte colony-stimulating factor ("G-CSF") analogs and compositions containing such analogs which retain the three-dimensional structure of the internal core of the four alpha helical bundle of G-CSF. In another aspect, such G-CSF analogs can also be attached with biologically active proteins to form hybrid molecules and still retain G-CSF structural integrity. Also provided are methods for determining and preparing analog or hybrid molecules and modifications.
The present invention relates to granulocyte colony-stimulating factor ("G-CSF") hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions containing hybrid molecules.
The present invention relates to granulocyte colony-stimulating factor ("G-CSF") hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions containing hybrid molecules.
Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.
